



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/824,095	04/13/2004	Eiichi Ueda	KON-1870	6153
20311 7590 12/12/2008 LUCAS & MERCANTI, LLP 475 PARK AVENUE SOUTH 15TH FLOOR NEW YORK, NY 10016				
EXAMINER				
PERREIRA, MELISSA JEAN				
ART UNIT		PAPER NUMBER		
1618				
MAIL DATE		DELIVERY MODE		
12/12/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/824,095

Applicant(s)

UEDA ET AL.

Examiner

MELISSA PERREIRA

Art Unit

1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 November 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 21-46 is/are pending in the application.
- 4a) Of the above claim(s) 46 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 21-45 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/CDC)
- 4) ☐ Interview Summary (PTO-413)
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____
- Paper No(s)/Mail Date _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/19/08 has been entered.

Claims and Previous Rejections Status

2. Claims 21-46 are pending in the application. Claim 46 is withdrawn from consideration as the identifier recites (withdrawn).
3. The rejection of claim 27 under 35 U.S.C. 102(b) as being anticipated by Na et al. (US 5,326,552) is withdrawn.
4. The provisional rejection of claims 21,22 and 26 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim claims 1,4,6,8-10 and 19 of copending Application No. 11/180,849 is maintained as no terminal disclaimer has been filed.
5. The provisional rejection of claims 21,22,25 and 27 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1,5-8,10-12 and 14-17 of copending Application No. 11/187,397 is maintained as no terminal disclaimer has been filed.

6. The rejection of claims 21-43 under 35 U.S.C. 103(a) as being unpatentable over Otake et al. (US2004/0099976A1) or Castor (US 5,554,382) in view of Sachse et al. (*Invest. Radiol.* **1997**, 32, 44-50; pages provided are numbered 1-8) and further in view of Mackaness et al. (US 4,192,859) is maintained.

7. The rejection of claims 21-42,44 and 45 under 35 U.S.C. 103(a) as being unpatentable over Otake et al. (US2004/0099976A1) or Castor (US 5,554,382) in view of Sachse et al. (*Invest. Radiol.* **1997**, 32, 44-50; pages provided are numbered 1-8) and further in view of Klaveness et al. (US 5,676,928) is maintained.

Oath/Declaration

8. The declaration under 37 CFR 1.132 filed 11/19/08 is insufficient to overcome the rejection of claims 21-45 based upon the rejections as set forth in the last Office action because:

9. The reference of Otake et al. (US2004/0099976A1) teaches that the liposomes of the disclosure have varying trapping efficiencies based on the phospholipid and the amount of added water (see fig 8). The liposomes of Otake et al. have trapping efficiencies of as high as 45% for DOPC. The declaration provides data for only one phospholipid, DPPC (which doesn't show the highest trapping efficiency in fig 8) and does not provide for the amount of added water and therefore the declaration does not provide enough data to show that the liposomes of the instant invention provides unexpected results with regards to the trapping efficiencies.

Claim Rejections - 35 USC § 112

10. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

11. Claims 21-45 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It is unclear as to what constitutes "substantially no chlorinated solvent" as the specification does not provide any guidance as how to determine a "substantially" acceptable amount of chlorinated solvent.

Claim Rejections - 35 USC § 103

12. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

13. Claims 21-43 are rejected under 35 U.S.C. 103(a) as being unpatentable over Otake et al. (US2004/0099976A1) or Castor (US 5,554,382) in view of Sachse et al. (*Invest. Radiol.* **1997**, 32, 44-50; pages provided are numbered 1-8) and further in view of Mackaness et al. (US 4,192,859).
14. Otake et al. (US2004/0099976A1) discloses the use of supercritical carbon dioxide for the single-step preparation of unilamellar liposomes, 50nm to 80nm in diameter that encapsulate a desired substance without the use of harmful organic solvents (abstract; p3, [0035]). The liposome preparation involves adding an aqueous

solution (to be encapsulated) to a mixture of a phospholipids and/or glycolipid and carbon dioxide under super critical conditions (p1, [0019]-[0020]; p2, [0021] and [0028]-[0029]). This preparation does not require the addition of a cosolvent but optionally can include a cosolvent (p3, [0035]) and the liposomes of the present invention are free of harmful organic solvents (including chlorinated solvent) and toxicity caused by such solvents (p3, [0037]). Carbon dioxide under super critical condition is meant to represent carbon dioxide at or above critical temperature (30.98°C) and pressure (7.3773 Mpa) (p2, [0022]). It is clearly stated that the liposomes are prepared in aqueous medium and that a cosolvent is **optionally** added (p3, [0035]) also example 1 shows the preparation of a liposome without the use of any cosolvent (p4, [0068]). The liposomes of the disclosure have improved trapping efficiency which is based on the type of phospholipid and amount of added water (abstract; fig 8; p2, [0021])

15. Castor (US 5,554,382) discloses the method of producing unilamellar (column 4, line 34) liposomes that are free of organic solvents (including chlorinated solvent) in supercritical CO₂ (column 2, lines 50-56; column 3, line 35). The method of preparing the liposomes involves mixing phospholipids in an aqueous phase (optionally containing a therapeutic agent) with a supercritical CO₂ (column 3, lines 41-47; column 9, lines 28-31). The resulting liposomes can be filtered through a 0.22 micron filter to reduce the 0.06mm critical fluid liposomes by 50% to yield liposomes of size 105 nm (column 10, lines 60-61). It is clearly stated that the liposomes are prepared in aqueous medium and that a cosolvent or entrainer is **optionally** added (i.e. with or without entrainer) (column 8, line 43; column 9, lines 29-32).

16. Neither Otake et al. or Castor disclose the inclusion of a PEGylated lipid or sterol. Also, Neither Otake et al. or Castor disclose the inclusion of an iodine compound in the preparation of the liposomes or residual iodine compound in the non-enclosed aqueous medium.

17. Sachse et al. (*Invest. Radiol.* **1997**, 32, 44-50; pages provided are numbered 1-8) discloses an Iopromide-containing liposomes for enhancing CT imaging (p2, paragraph 1). The liposomes contain soy phosphatidylcholine (SPC), cholesterol, soy phosphatidylglycerol (SPG) (6:3:1 molar ratio) and 5 mol% DPSE-PEG2000 which is administered intravenously into a rat tail vein at a dose of 250mg I/kg = 500 mg/kg lipid (p3, paragraphs 1 and 4). The Iopromide-containing liposomes are used without prior removal of the unencapsulated contrast agent (p3, results). Sachse et al. also discloses that the PEGylated lipid derivatives in the liposome are 204 nm (p3, results) and provide for potent increase in circulation times (p1, paragraph 2) as they avoid the mononuclear phagocytic system (MPS) and target to non-MPS organs.

18. Neither Otake et al. or Castor disclose the inclusion of a water-soluble amine compound in the preparation of the liposomes.

19. Mackaness et al. (US 4,192,859) discloses a liposomal X-ray contrast medium having cavities containing the contrast agent therein (column 2, lines 48-52). The contrast agents suitable for use are sodium diatrizoate, iodipamide, iodamide, etc. and are present in 20-60% by weight of the contrast medium (column 3, lines 24-29). The materials constituting the liposome include phospholipids (phosphatidyl choline), lecithin, dicetyl phosphate, sterols (cholesterol) and stearylamine (column 3, lines 36-

39). These materials may be used in binary or ternary mixtures including mixtures of lecithin and cholesterol where the percentage of lecithin may range from 55-85% and the sterol from about 15-35% (column 3, lines 64+). The contrast medium is prepared by addition of the liposome to a buffer solution containing iodine containing contrast agent where the contrast agent is trapped within the liposome vesicle (see examples). The pH consistency and viscosity of the final liposome preparations are controlled by the nature and amount of phospholipid used (column 4, lines 14-20).

20. It is respectfully pointed out that instant claims 27-45 are product-by-process limitations. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process. In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed Cir. 1985). See MPEP 2113.

21. At the time of the invention it would have been obvious to one ordinarily skilled in the art to utilize the PEGylated lipid derivative in the supercritical carbon dioxide preparation method of Otake et al. or Castor since it makes it possible to produce these modified unilamellar liposomes with potent increase in circulation times (p1, paragraph 2) as they avoid the mononuclear phagocytic system (MPS) and target to non-MPS organs. The resulting liposomes have improved trapping efficiency, based on the phospholipid and amount of added water used, in a preparation with fewer steps and without using harmful organic solvents (fig 8). The extreme conditions used with

multiple step syntheses using harmful organic solvents can cause the denaturation of the phospholipids raw material. The push for green chemistry (without the use of harmful organic solvents) has been prevalent in recent years not only for the safety of humans but also to reduce the detrimental effects of such solvents on the environment. It would be obvious to one ordinarily skilled in the art to utilize known synthetic techniques minimizing or eliminating harmful organic solvents. In addition, the method of preparing the liposomes of Castor via supercritical carbon dioxide imparts an increased level of stability to the liposomes (column 18, 34-42). The liposomes of Castor are used for the method of drug delivery and would therefore be adaptable to the inclusion of the iodinated compound (column 6, lines 8-10; column 19, lines 58-60) of Sachse et al. The references above are drawn to the same utility, preparation of lipid containing liposomes, and therefore it would be obvious to utilize/try/include the sterol and stearylamine of Sachse et al. and/or Mackaness et al. via the methods of Otake et al. or Castor.

22. The preparation of the liposomes containing iodinated contrast medium of the combined disclosures encompasses that of the instant claims and therefore generates liposomes containing iodinated contrast agents that encompass those of the instant claims which should be capable of satisfying the same requirements and have the same properties. Furthermore, it is obvious to vary and/or optimize the amount of (compound) provided in the composition, according to the guidance provided by (reference), to provide a composition having the desired properties such as the desired (ratios, concentrations, percentages, etc.). It is noted that "[W]here the general conditions of a

claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

23. Claims 21-42,44 and 45 are rejected under 35 U.S.C. 103(a) as being unpatentable over Otake et al. (US2004/0099976A1) or Castor (US 5,554,382) in view of Sachse et al. (*Invest. Radiol.* **1997**, 32, 44-50; pages provided are numbered 1-8) and further in view of Klaveness et al. (US 5,676,928).

24. Otake et al. (US2004/0099976A1) discloses the use of supercritical carbon dioxide for the single-step preparation of unilamellar liposomes, 50nm to 80nm in diameter that encapsulate a desired substance without the use of harmful organic solvents (abstract; p3, [0035]) as well as that stated above.

25. Castor (US 5,554,382) discloses the method of producing unilamellar (column 4, line 34) liposomes that are substantially free of organic solvents in supercritical CO₂ (column 2, lines 50-56; column 3, line 35) as well as that stated above.

26. Neither Otake et al. or Castor disclose the inclusion of a PEGylated lipid or sterol. Also, Neither Otake et al. or Castor disclose the inclusion of an iodine compound in the preparation of the liposomes or residual iodine compound in the non-enclosed aqueous medium.

27. Sachse et al. (*Invest. Radiol.* **1997**, 32, 44-50; pages provided are numbered 1-8) discloses an Iopromide-containing liposomes for enhancing CT imaging (p2, paragraph 1). The liposomes contain soy phosphatidylcholine (SPC), cholesterol, soy

phosphatidylglycerol (SPG) (6:3:1 molar ratio) and 5 mol% DPSE-PEG2000 as well as that stated above.

28. Neither Otake et al. or Castor disclose the inclusion of a trometamol or EDTA disodium calcium chelating agents in the preparation of the liposomes.

29. Klaveness et al (US 5,676,928) discloses a liposomal contrast agent encapsulating an iodine imaging agent (iodixanol) for use in X-ray (claims 13 and 14). These unilamellar liposomes (column 9, lines 36-50) have a high encapsulation capacity, 5-6 ml/g and a typical concentration of 10-300mg of encapsulated iodine per ml composition. The iodine imaging agent is contained within the liposome and the liposome suspended in an aqueous medium containing the same iodinated imaging agent and a buffering solution (column 4; column 8, lines 3-9). Any biocompatible gas, such as carbon dioxide or stabilizing agent, such as EDTANa₂Ca or Trometamol may be present (column 6, line 1; column 10, line 23; example 8). The total lipid concentration is generally 20mg/ml to 100mg/ml (column 7, lines 64+). In an effort to obtain the desired particle size, 50nm to 3000nm the liposomes may be passed through a filter with a predetermined pore size (column 9, lines 28-33).

30. It is respectfully pointed out that instant claims 27-45 are product-by-process limitations. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is

unpatentable even though the prior product was made by a different process. In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed Cir. 1985). See MPEP 2113.

31. At the time of the invention it would have been obvious to one ordinarily skilled in the art to utilize the PEGylated lipid derivative in the supercritical carbon dioxide preparation method of Otake et al. or Castor since it makes it possible to produce these modified unilamellar liposomes with potent increase in circulation times (p1, paragraph 2) as they avoid the mononuclear phagocytic system (MPS) and target to non-MPS organs. The resulting liposomes have improved trapping efficiency, based on the phospholipid and amount of added water used, in a preparation with fewer steps and without using harmful organic solvents. The extreme conditions used with multiple step syntheses using harmful organic solvents can cause the denaturation of the phospholipids raw material. The push for green chemistry (without the use of harmful organic solvents) has been prevalent in recent years not only for the safety of humans but also to reduce the detrimental effects of such solvents on the environment. It would be obvious to one ordinarily skilled in the art to utilize known synthetic techniques minimizing or eliminating harmful organic solvents. In addition, the method of preparing the liposomes of Castor via supercritical carbon dioxide imparts an increased level of stability to the liposomes (column 18, 34-42). The liposomes of Castor are used for the method of drug delivery and would therefore be adaptable to the inclusion of the iodinated compound (column 6, lines 8-10; column 19, lines 58-60) of Sachse et al. The references above are drawn to the same utility, preparation of lipid containing liposomes, and therefore it would be obvious to utilize/try/include the sterol and

stabilizing agent, such as EDTANa₂Ca or Trometamol of Sachse et al. and/or

Klaveness et al. respectively via the methods of Otake et al. or Castor.

32. The preparation of the liposomes containing iodinated contrast medium of the combined disclosures encompasses that of the instant claims and therefore generates liposomes containing iodinated contrast agents that encompass those of the instant claims which should be capable of satisfying the same requirements and have the same properties. Furthermore, it is obvious to vary and/or optimize the amount of (compound) provided in the composition, according to the guidance provided by (reference), to provide a composition having the desired properties such as the desired (ratios, concentrations, percentages, etc.). It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 US.

Double Patenting

33. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to

be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 21,22 and 26 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim claims 1,4,6,8-10 and 19 of copending Application No. 11/180849. Although the conflicting claims are not identical, they are not patentably distinct from each other because both applications disclose the method of preparing a radiographic contrast medium comprising a unilamellar liposome by mixing a polyalkylene oxide modified phospholipid and a sterol with an aqueous solution containing a water-soluble iodine compound via supercritical carbon dioxide.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 21,22,25 and 27 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1,5-8,10-12 and 14-17 of copending Application No. 11/187,397. Although the conflicting claims are not identical, they are not patentably distinct from each other because both applications disclose the method of preparing a liposome containing a water-soluble iodine compound, sterols and polyalkylene compounds via supercritical carbon dioxide under increased temperature and pressure. Filtration of the desired iodine containing liposomes is also disclosed in both applications. Further disclosed in both applications is a liposome-containing preparation generated by the method above.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Response to Arguments

34. Applicant's arguments filed 11/19/08 have been fully considered but they are not persuasive.

35. Applicant asserts that the instant claims recite that the liposome is made with a compound selected from the group consisting of a phospholipid modified with a polyalkylene oxide and a compound containing a polyalkylene group and that none of the references teach such an addition to the liposome or the fact that including such in the liposome will result in increased inclusion of the encapsulated compound.

36. The reference of Otake et al. teaches that the liposomes of the disclosure have improved trapping efficiency which is based on the type of phospholipid and amount of added water (abstract; fig 8; p2, [0021]). The liposomes of Otake et al. have trapping efficiencies of as high as 45% for DOPC. Sachse et al. discloses that a PEGylated lipid derivatives in the liposome (p3, results) provides for potent increase in circulation times (p1, paragraph 2) as they avoid the mononuclear phagocytic system (MPS) and target to non-MPS organs. Therefore it would have been obvious to one skilled in the art to create a liposome via the method of Otake et al. for improved trapping efficiency (as high as 45%) with a PEGylated lipid derivative to generate a liposome with increase in circulation times.

Conclusion

No claims are allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA PERREIRA whose telephone number is (571)272-1354. The examiner can normally be reached on 9am-5pm M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/
Supervisory Patent Examiner, Art Unit 1618

/Melissa Perreira/
Examiner, Art Unit 1618